<DOC>
	<DOC>NCT01891708</DOC>
	<brief_summary>a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer</brief_summary>
	<brief_title>VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description>1. non small cell lung cancer (non squamous carcinoma) 2. ECOG 0-1 3. from 18-75 years old</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>non squamous cell non small cell lung cancer with measurable disease ECOG 01 patients received surgery in recent 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>